FDA Scales Back Domestic Inspections Due To Coronavirus
Agency Will Focus On Safety Of Regulated Products
After postponing foreign inspections, the US FDA has further decided to scale back domestic inspections due to the coronavirus outbreak.
You may also be interested in...
The US FDA is postponing “most foreign inspections” through April as a result of the coronavirus outbreak, because it will temporarily not be able to physically inspect foreign produced FDA-regulated products or manufacturers. However, inspections outside the US deemed as critical “will still be considered on a case-by-case basis.”
Despite the delay in a New York state opioid trial due to coronavirus, a motion has been filed to remove Mallinckrodt and SpecGx from proceedings. However, Nassau County opposed the motion.
Alvotech has partnered with DKSH to bring its high-concentration Humira rival to Asia. The Alvogen sister company plans to file the adalimumab biosimilar with the EMA and FDA in the second half of 2020.